Longeveron (LGVN) Liabilities and Shareholders Equity (2021 - 2026)
Longeveron (LGVN) recorded quarterly Liabilities and Shareholders Equity of $21.2 million in Q1 2026, up 106.7% quarter-over-quarter from $10.3 million in Q4 2025, and up 1.74% on a YoY basis from $20.8 million in Q1 2025.
Longeveron (LGVN) Liabilities and Shareholders Equity (2021 - 2026) Analysis & Trends
Longeveron's Liabilities and Shareholders Equity history runs 6 years deep, the most recent figure standing at $21.2 million for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity rose 1.74% year-over-year to $21.2 million; the TTM figure through Mar 2026 stood at $63.8 million (down 33.36% YoY), while the FY2025 annual figure was $10.3 million, down 59.85% from the prior year.
- Liabilities and Shareholders Equity was $21.2 million for Q1 2026 at Longeveron, up from $10.3 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $29.9 million in Q3 2024 to a low of $9.7 million in Q1 2024.
- Historically, Liabilities and Shareholders Equity has averaged $18.5 million across 5 years, with a median of $18.2 million in 2023.
- The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity soared 157.28% in 2024, then sank 59.85% in 2025.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $27.4 million in 2022, then tumbled by 55.94% to $12.1 million in 2023, then soared by 111.61% to $25.6 million in 2024, then tumbled by 59.85% to $10.3 million in 2025, then jumped by 106.7% to $21.2 million in 2026.
- The last three Liabilities and Shareholders Equity figures came in at $21.2 million (Q1 2026), $10.3 million (Q4 2025), and $15.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 37.37 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 811.27 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 14.93 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.73 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 23.64 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 33.89 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 12.81 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 26.48 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 640.56 Mn |
| 10 | Longeveron | 20.35 Bn | 20.33 Bn | 264,000.00 | 21.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21.21 Mn |
| Dec 31, 2025 | 10.26 Mn |
| Sep 30, 2025 | 15.56 Mn |
| Jun 30, 2025 | 16.75 Mn |
| Mar 31, 2025 | 20.85 Mn |
| Dec 31, 2024 | 25.56 Mn |
| Sep 30, 2024 | 29.91 Mn |
| Jun 30, 2024 | 19.39 Mn |
| Mar 31, 2024 | 9.70 Mn |
| Dec 31, 2023 | 12.08 Mn |
| Sep 30, 2023 | 11.63 Mn |
| Jun 30, 2023 | 17.09 Mn |
| Mar 31, 2023 | 21.81 Mn |
| Dec 31, 2022 | 27.41 Mn |
| Dec 31, 2021 | 42.77 Mn |